Gyre Therapeutics Inc. (NASDAQ: GYRE)
$15.71
+1.7500 ( +12.54% ) 65.4K
Gyre Therapeutics Inc is a biopharmaceutical company headquartered in San Diego, CA, that is primarily focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis), formerly known as Nonalcoholic Steatohepatitis (NASH)) in the United States. In the United States, Hydronidone is currently being evaluated for the treatment of liver fibrosis across a broad spectrum of chronic liver diseases under an active Investigational New Drug (IND) application. Gyre is also advancing a diverse pipeline in China through a controlling interest in the Beijing Continent, including pirfenidone, F573, F528, and F230.
Market Data
Open
$15.71
Previous close
$13.96
Volume
65.4K
Market cap
$1.34B
Day range
$13.97 - $15.67
52 week range
$5.88 - $30.40
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
8-k | 8K-related | 13 | Jul 05, 2024 |
4 | Insider transactions | 1 | Jul 01, 2024 |
8-k | 8K-related | 14 | Jun 17, 2024 |
8-k | 8K-related | 15 | May 30, 2024 |
10-q | Quarterly Reports | 88 | May 13, 2024 |
8-k | 8K-related | 13 | May 09, 2024 |
8-k | 8K-related | 14 | May 08, 2024 |
4 | Insider transactions | 1 | May 02, 2024 |
def | Proxies and info statements | 6 | Apr 29, 2024 |
ars | Annual reports | 1 | Apr 29, 2024 |